Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × pembrolizumab × Endocrine × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

OTHER 17 INDUSTRY 5 OTHER_GOV 1 NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 3 Dermatologic 3 Thoracic 2 Other solid neoplasm 2 Gynecologic 2 Sarcoma 1 Gastrointestinal 1 Endocrine 1 CNS 1

Conditions

Adrenocortical Carcinoma 1

Interventions

Observation 2 pembrolizumab 1 olaparib 1 lenvatinib 1 copper dotatate CU-64 1 Tomography, Emission-Computed, Single-Photon 1 Thyroidectomy 1 Reverse Transcriptase Polymerase Chain Reaction 1 PM 01183 1 Lymph Node Excision 1 Lutetium-177 1 Irinotecan 1 Iodine-124 1 Iodine-123 1 Injections 1 Histocompatibility Testing 1 Etoposide 1 Cisplatin 1 Catecholamines 1 Capecitabine 1 Blood Specimen Collection 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05036434 2026-01-23

ACCOMPLISH

National Cancer Center, Korea

Phase 2 Active not recruiting

Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡